National and Kapodistrian University of Athens
Διερεύνηση της καρδιοπροστατευτικής δράσης και του υποκείμενου μηχανισμού δράσης βιοδραστικών συστατικών της ελιάς και του συνδυασμού τους σε in vivo πειραματικά μοντέλα μεταβολικού συνδρόμου
Abstract
dc:descriptionIntroduction: Clinical studies have previously established the role of olive products in cardiovascular disease (CVD) prevention, whilst the identification of the constituents or compound combinations responsible for the beneficial effects is still pending. Purpose: We sought to assess and compare the potential cardioprotective effects of oleuropein (OL), hydroxytyrosol (HT), oleocanthal (OC) and oleanolic acid (OA), regarding Ischemia/Reperfusion Injury (IRI) and CVD risk factors alleviation. According to the effects of each isolated compound on myocardial infarct size and MS parameters, we designed three combinational treatments with expected additive cardiovascular benefits. Our ultimate goal was the design of a potent and safe combinational therapy for high-cardiovascular-risk patients on a bench-to-bedside approach. Methods: Male C57Bl6 mice were randomized and received OL (20.6 mg/kg), HT (5.9 mg/kg), OC (11.6 mg/kg), OA (17.4 mg/kg) or vehicle (DMSO 5%) 6 weeks daily by oral gavage. At the end of week 6, all animals were subjected to 30min of myocardial ischemia followed by 2h reperfusion. The heart was excised and double stained for infarct size measurement. Next, we induced MS in C57Bl6 mice by feeding with western-type diet for 14 weeks. Mice were treated with one of the isolated compounds or vehicle for the last 6 weeks and IRI was induced at 14 weeks. At baseline, on weeks 8 and 14 we performed blood collection, weighing, fasting blood glucose determination, arterial blood pressure measurement and heart function was assessed by echocardiography. According to the observed effects, three combinational treatments (OL-HT-OA, OL-HT-OC and OL-HT-OC-OA) were investigated for their cardioprotective potential in the MS mouse model of IRI. The combinational treatment with the most favorable effects (OL-HT-OC) was further tested for potential antiatherosclerotic effects after 4-week administration in ApoE-/- mice and investigated for the underlying cardioprotective mechanism in C57Bl6 mice with MS by determining the expression of specific proteins in the ischemic myocardium. After ensuring safety of the combinational therapy OL-HT-OC in the selected and triple dose in healthy mice, we proceeded to evaluate the potential effects of OL-HT-OC supplement in patients with Chronic Coronary Artery Syndrome (CCAS). Cardiac function, inflammation markers and oxidative stress were assessed at baseline and after 4 weeks of treatment with the OL-HT-OC supplement. Results: We found that OL, OC and OA, but not HT, significantly reduced infarct size compared to vehicle-treated groups, in both healthy and MS-burdened mice. Diet- induced MS was established as the coexistence of elevated fasting blood glucose, total plasma cholesterol and body weight. OL exhibited antihyperglycemic properties by reducing fasting blood glucose and increasing insulin levels, while OA attenuated hypercholesterolemia. None of the bioactive compounds altered the increased body weight, nor the arterial pressure and echocardiographic parameters of myocardial function. OL-HT-OA, OL-HT-OC and OL-HT-OC-OA combinational treatments were cardioprotective, whereas only OL-HT-OC mitigated hyperglycemia. OL-HT-OC cardioprotection was attributed to apoptosis suppression and upregulation of antioxidant enzymes in the ischemic myocardium. Additionally, OL-HT-OC treatment reduced atherosclerotic plaque extent in vivo and low-density lipoprotein oxidation in vitro. No signs of toxicity were present after 4 weeks of administration in both tested doses. OL-HT-OC combinational treatment ameliorated cardiac, vascular and endothelial function in patients with CCAS. Conclusion: OL-HT-OC combinational therapy exerts potent cardioprotective, antihyperglycemic and antiatherosclerotic properties in vivo, with remarkable and clinically translatable cardiovascular benefits in high-risk patients. Our study provides valuable insight on the pleiotropic effects of olive products and the possible contradicting or synergistic effects that may arise in more complex mixtures, paving the way to leveraging their biological activities in clinical practice.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Christodoulou, Andriana
- Χριστοδούλου, Ανδριάνα
Subjects
dc:subject × 18- Καρδιαγγειακή νόσος
- Mεταβολικό σύνδρομο
- Ολευρωπαΐνη
- Υδροξυτυροσόλη
- Ολεοκανθάλη
- Ολεανολικό οξύ
- Cardiovascular disease
- Metabolic syndrome
- Oleuropein
- Hydroxytyrosol
- Oleocanthal
- Oleanolic acid
- Βασική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Φαρμακολογία και Φαρμακευτική
- Basic Medicine
- Medical and Health Sciences
- Pharmacology and Pharmacy
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/57610